Abbott Laboratories (ABT): revenue growth, 5-year cagr, 10 filed years
Revenue CAGR 5y at Abbott Laboratories was 5.1% in FY2025, the newest filed year. Across the 8 computed years from FY2016 it ranged from -11.7% (FY2016) to 15.6% (FY2021), with a median of 5.6%.
Tonight's figure on the company page: 5.1%, recomputed 2026-10-15. The table is each filed year on its own terms, with the formula below; the current figure may use trailing twelve months or, where the explainer says so, a different denominator.
Year by year
| Fiscal year | Revenue CAGR 5y | Read from |
|---|---|---|
| FY2016 | -11.7% | 10-K, filed 2017-02-17 |
| FY2017 | -7.2% | 10-K, filed 2018-02-16 |
| FY2018 | 7.0% | 10-K, filed 2019-02-22 |
| FY2019 No positive revenue is on file for the fiscal year five years earlier, so a five-year growth rate cannot be computed. | n/a | 10-K, filed 2020-02-21 |
| FY2020 No positive revenue is on file for the fiscal year five years earlier, so a five-year growth rate cannot be computed. | n/a | 10-K, filed 2021-02-19 |
| FY2021 | 15.6% | 10-K, filed 2022-02-18 |
| FY2022 | 9.8% | 10-K, filed 2023-02-17 |
| FY2023 | 5.6% | 10-K, filed 2024-02-16 |
| FY2024 | 5.6% | 10-K, filed 2025-02-21 |
| FY2025 | 5.1% | 10-K, filed 2026-02-20 |
How each year is computed
(Revenue this year / revenue five fiscal years earlier)^(1/5) - 1, x 100
Each year is a ratio of lines in that year's filed annual report, with the nightly recompute's own rules for what counts as a filed line. Nothing is estimated, smoothed or filled in: a year that cannot be computed says why.
Read further
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.